Eli Lilly and Company announced a series of changes that will make their insulins more affordable. This includes a reduction in the list price of Insulin Lispro (non-branded Humalog®) to $25 a vial, a reduction in the list price of Humalog®, and the launch of a basal insulin that is biosimilar to, and interchangeable with, Lantus®. They are also expanding their Insulin Value Program which will cap out-of-pocket costs for insulin at $35 a month for those with insurance and those without who use the Lilly Insulin Value Program savings card.

This is a promising step forward in the fight for insulin affordability. JDRF will continue to work with all stakeholders, including policy makers and industry, and support efforts like the Civica Insulin Initiative to keep the momentum going.